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Modification and Stabilization of MHC Class I Molecules  
for use in DNA Vaccines 
Gregory Cresswell 
Department of Microbiology 
Dr. John Martinko 
Abstract Results and Discussion 
Major Histocompatibility Complex class I molecules present 
antigens to the immune system.  A mouse MHC class I gene, 
H-2Kb, was modified by linking individual subunits together with a 
peptide antigen to form a single chain trimer (SCT).  A disulfide 
bond, termed the disulfide trap, was added to stabilize the 
preloaded antigen (Figure 1 and Figure 2).  The original antigen 
peptide, SIINFEKL, was modified to test the disulfide trap for 
stabilization of MHC class I SCT with a modified antigen.  The 
SIINFEKL antigen was modified to SIINHEKL and SIINYEKL.  DNA 
primers were designed to mutate the phenylalanine (F) amino acid 
to histidine (H) or tyrosine (Y).  This was done through site directed 
mutagenesis, transformation, and transfection into tissue culture 
cells.  Modifications of the peptide were tested using B3Z T cells 
that specifically recognize the SIINFEKL-Kb epitope.  Cells 
expressing the disulfide trap proved to be very stable and 
presented a recognizable antigen to the T cells even when the 
original peptide had been modified.  SCTs without the disulfide trap 
were weakly presented to the T cells.  SCTs containing the mutant 
SIINYEKL or SIINHEKL peptides lacking the disulfide trap were not 
as stable and did not fold or present peptides well.  In particular, 
the SIINHEKL modification showed that the disulfide trapped SCT 
was recognized by the T cells.  However, the non-trapped  
SIINHEKL showed a significant reduction in epitope expression.  
The SIINYEKL mutants showed similar results.  This indicates that 
peptides of our design can be presented efficiently to the immune 
system with disulfide trap stabilization.  Further application of this 
research may allow construction of DNA vaccines expressing 
custom antigens. 
The cell lines were then analyzed for expression of the SCT MHC 
Class I through a B3Z Assay. 
B3Z Assay 
B3Z T cells carry the lac Z operon and have T cell receptors specific 
for the SIINFEKL-Kb epitope. These cells were used to measure 
expression of the SCT in transfected cell lines. B3Z cells that bound 
the SCTs were activated and cleaved MUG ( a lac Z  substrate) to 
generate a color change.  This was quantitatively measured to 
determine expression.   
Methods 
Site-Directed Mutagenesis 
DNA primers were designed to mutate the original SIINFEKL    
peptide to the new peptides SIINHEKL and SIINYEKL.  Both disulfide 
trap and non-disulfide trap models were created. 
Transformation 
The mutated strands were then transformed into E. coli for 
amplification of the DNA.  The plasmid carrying the DNA carries 
genes for ampicillin resistance.  The E. coli were grown on LB agar 
with 50 µg/mL of ampicillin.  Once grown on plates, resistant colonies 
from the plates were transferred to LB broth with 50 µg/mL of 
ampicillin.  Ten liquid cultures were made and then used for DNA 
extraction. 
Plasmid Preparation 
A plasmid preparation was used  extract the DNA from the E. coli 
liquid cultures.   
DNA Gel Electrophoresis 
The purified DNA from the plasmid preparation was then cut with the 
BamH1 restriction enzyme.  This cuts the DNA into fragments for 
visualization on the gel.   
Transfection 
293T cells were used to generate viral particles carrying the mutated 
DNA strands.  Those viral particles were then used on LM18 mice 
cells to create a new cell line expressing SIINHEKL or SIINYEKL.  
The plasmid tranfsected into the cell lines carried genes for 
hgyromycin resistance.  This was used as the selective agent to 
eliminate non-transfected cells.   
Figure 3. T cell epitope assay of SCT MHC proteins.  B3Z T cells, specific for the SIINFEKL–Kb 
MHC I epitope were used to assay the expression levels of both natural and mutated versions of the 
epitope in transfected cell lines.  YC: SIINYEKL with the disulfide trap.  YA: SIINYEKL without the 
disulfide trap. HC: SIINHEKL with disulfide trap.  HA: SIINHEKL without disulfide trap.  FC: 
SIINFEKL with disulfide trap.  FA: SIINFEKL without disulfide trap.  S:  Cell line that has been kept 
under selective pressure.  B3Z are the B3Z cells alone.  Lm18 is a cell line that is not expressing 
the Kb epitope.  Lm18 Kb is a cell line expressing only the Kb epitope and not the SCT.    
 We showed that an SCT model of the MHC class I molecule 
can be generated and expressed in cell lines.  All class I MHC  SCT 
molecules generated in this study are recognized by the B3Z T cell, 
indicating that the mutations introduced to generate the disulfide trap 
to alter the major anchor residues in SIINFEKL did not destroy the T 
cell epitope: with or without the disulfide trap, the native SIINFEKL 
SCT and the SCTs containing the SIINHEKL and SIINYEKL peptides 
maintained T cell epitope expression. The B3Z T cells specific for the 
SIINFEKL peptides recognized the altered peptides and disulfide 
trapped constructs in every case.   
  With the native SIINFEKL peptide, the disulfide trap partially   
reduced expression of the T cell epitope (Figure 3).  In the both 
cases where the native peptide was altered, however, the disulfide 
trap provided increased T cell epitope stability; both SIINYEKL and 
SIINHEKL disulfide trapped molecules were recognized better than 
the non-trapped molecules ( Figure 3).  This was especially evident  
for SIINHEKL where the non-disulfide trapped molecule showed  
significantly reduced expression of the T cell epitope, relative to all 
other SCT constructs.  The disulfide-trapped SIINHEKL molecule, on 
the other hand, showed enhanced expression of the T cell epitope, 
indicating significant stabilization of the epitope due to the disulfide 
trap.   
 The native SIINFEKL-Kb SCT is shown with and without 
disulfide trap along with cell lines that were kept under antibiotic  
selective pressure to enhance expression of the SCT DNA.  There 
were no observable difference in SCT expression between cells kept 
under selection and those that were not kept under selection; the 
comparison between selected and unselected cell lines did not 
significantly alter surface recognition of the T cell epitope, indicating 
that selective pressure is not needed for the cells to maintain and 
express the transfected DNA.  Thus, the SCT disulfide trapped MHC 
is very stable once it has been introduced into the cell.  This stability 
is further proof of concept for application in DNA vaccines.        







Figure 1. Single Chain Trimer MHC Class I Molecule 
The alpha chain (blue) is linked (red) to the β2-microglobulin (purple)  
and the peptide is connected to the linker (red) on the β2-microglobulin. 
The disulfide trap is in green. 
Image taken from Journal of Immunology 2007. 
Figure 2. The disulfide trap site. Tyr84 is replaced with cysteine in the disulfide trap. 
Image taken from Journal of Immunology 2007. 
